• Home
  • Low-DMSO Cryopreservation of MSCs with Optibumin 25 Recombinant Albumin

Low-DMSO Cryopreservation of MSCs with Optibumin 25 Recombinant Albumin

Published on 15 June 2025

Application Note

Authors: Andrew Hamann, PhD & Mark Stathos, PhD
InVitria, Inc., Junction City, KS, USA

Overview
This application note evaluates the use of Optibumin® 25—a recombinant, animal-origin-free human serum albumin—for low-DMSO cryopreservation of umbilical cord-derived mesenchymal stem cells (UC-MSCs). The study demonstrates that Optibumin enables DMSO reduction to as low as 1% while maintaining post-thaw MSC viability and reducing apoptosis, matching or outperforming blood-derived HSA.

Key Findings

  • Maintains MSC viability at 1–2.5% DMSO
  • Reduces apoptosis vs. no-albumin controls
  • Performs as well or better than human blood-derived HSA
  • Supports closed-system, regulatory-friendly manufacturing